MMWR. Morbidity and mortality weekly report最新文献

{"title":"Vaccination Coverage by Age 24 Months Among Children Born in 2021 and 2022 - National Immunization Survey-Child, United States, 2022-2024.","authors":"Holly A Hill, David Yankey, Laurie D Elam-Evans, Yi Mu, Michael Chen, Shannon Stokley, Georgina Peacock, James A Singleton","doi":"10.15585/mmwr.mm7511a2","DOIUrl":"10.15585/mmwr.mm7511a2","url":null,"abstract":"<p><p>The National Immunization Survey-Child monitors coverage with recommended routine childhood vaccines. For data collected in survey year 2024, which include children born in 2021 and 2022, the household response rate (23.4%) and availability of adequate provider data for children with completed interviews (51.4%) were comparable to those from earlier survey years. For most vaccines, coverage by age 24 months was similar among children born in 2021 and 2022 and those born in 2019 and 2020. Declines in coverage of 1-2 percentage points were observed for the primary series of Haemophilus influenzae type b conjugate vaccine, the birth dose of hepatitis B vaccine, ≥4 doses of pneumococcal conjugate vaccine, and rotavirus vaccine. Coverage with ≥2 doses of influenza vaccine by age 24 months decreased from 61.0% among children born during 2019-2020 to 53.5% among those born during 2021-2022. Coverage was lower among Vaccines for Children (VFC) program-eligible children than among those who were not VFC-eligible and differed substantially by jurisdiction. Compared with non-Hispanic White children, coverage with many vaccines was lower among non-Hispanic Black or African American and Hispanic or Latino children; coverage was highest among non-Hispanic Asian children. Coverage was also lower among children living in poverty and those living in more rural areas. Maintaining high levels of vaccination and improving coverage among groups and in areas in which rates have declined could help protect children from vaccine-preventable morbidity and mortality. The Community Preventive Services Task Force recommends several interventions to increase vaccination, including standing orders for vaccination, immunization information systems, and vaccination programs in organized child care centers and in Special Supplemental Nutrition Program for Woman, Infants, and Children settings. Other factors demonstrated to be effective include strong provider recommendations, targeted messages from credible and trusted sources, and increased participation in the VFC program.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 11","pages":"146-155"},"PeriodicalIF":16.2,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13020856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicounty Outbreak of Salmonella Agbeni Linked to Ice in a Cooler at a County Fair - Illinois, August 2024.","authors":"Katherine E Houser","doi":"10.15585/mmwr.mm7507a1","DOIUrl":"10.15585/mmwr.mm7507a1","url":null,"abstract":"<p><p>On August 5, 2024, the Brown County (Illinois) Health Department (BCHD) was informed by the county sheriff that numerous potential jurors being screened for an upcoming trial had reported recently experiencing a gastrointestinal illness. One week later, on August 12, a laboratory-confirmed case of Salmonella enterica serotype Agbeni infection was reported to BCHD by the Illinois Department of Public Health. Investigation by BCHD identified seven laboratory-confirmed and six probable cases of S. enterica serotype Agbeni illness across five Illinois counties. All persons who became ill had attended the Brown County fair in rural Illinois during July 30-August 4 and reported drinking beer served from a cooler in the fair's beer tent. No other common food or environmental exposures were identified. The cooler containing the beer was reused for multiple days and not cleaned. A generative artificial intelligence tool (ChatGPT 4.0, OpenAI; 2024) was used to assist with hypothesis generation during the investigation, supplementing traditional epidemiologic methods and contributing to identification of a shared, nonfood vehicle of transmission. This outbreak highlights the role of standardized hygiene protocols for cooler sanitation and beverage storage and handling at public events.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 7","pages":"93-97"},"PeriodicalIF":16.2,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12944811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.","authors":"Benjamin J Silk, Mila M Prill, Amber K Winn, Monica E Patton, Heidi L Moline, Michael Melgar, Kevin C Ma, Clinton R Paden, Lydia J Atherton, Diba Khan, Christopher A Taylor, Ayzsa Tannis, Kadam Patel, Leah A Goldstein, Krista Kniss, Angiezel Merced-Morales, Natalie Thornburg, Fatimah S Dawood","doi":"10.15585/mmwr.mm7506a2","DOIUrl":"10.15585/mmwr.mm7506a2","url":null,"abstract":"<p><p>Respiratory viruses are common causes of upper and lower respiratory tract illness and can also result in hospitalization and death. CDC conducts national surveillance using multiple systems to monitor ongoing and seasonal changes in the activity of selected respiratory viruses. This report summarizes U.S. trends in endemic respiratory virus activity during July 2024-June 2025. For SARS-CoV-2 and respiratory syncytial virus (RSV), national and regional trends; population-based hospitalization rates; vital records death counts; and preliminary estimates of associated illnesses, outpatient visits, hospitalizations, and deaths are described, as well as genetic characterization of circulating SARS-CoV-2 viruses. Some viruses, including SARS-CoV-2, showed bimodal peaks in positive laboratory test results, whereas others, including RSV and influenza viruses, were characterized by a single peak. The highest COVID-19-associated hospitalization rates were reported among adults aged ≥75 years (932.6 per 100,000 persons), infants aged <6 months (285.6), and adults aged 65-74 years (274.4). RSV-associated hospitalization rates were highest among infants aged <12 months (1,116.7 per 100,000; 95% CI = 1,078.4-1,157.9), children aged 12-23 months (770.6; 95% CI = 743.1-800.3), and adults aged ≥75 years (426.9; 95% CI = 366.6-510.8). COVID-19 was associated with an estimated 290,000-450,000 hospitalizations and 34,000-53,000 deaths; RSV was associated with 190,000-350,000 hospitalizations and 10,000-23,000 deaths. All circulating SARS-CoV-2 lineages were Omicron JN.1 descendants. Staying up to date with recommended COVID-19, RSV, and influenza vaccinations remains important to reducing the risk for severe disease caused by these viruses.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 6","pages":"77-84"},"PeriodicalIF":16.2,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025.","authors":"Julia Raykin, Ilia Rochin, Ryan Wiegand, Victoria Soto, Afua Nyame-Mireku, Amy Chung, Josephine Mak, Tegan Boehmer, Pragna Patel","doi":"10.15585/mmwr.mm7506a1","DOIUrl":"10.15585/mmwr.mm7506a1","url":null,"abstract":"<p><p>Adults aged ≥65 years have the highest rates of COVID-19-related hospitalization. Despite the proven benefit of COVID-19 antivirals in preventing severe outcomes, data suggest that their use is low among older adults. To assess factors associated with receipt of an antiviral prescription among adults aged ≥65 years examined in outpatient settings who received a positive SARS-CoV-2 test result or COVID-19 diagnosis during June 1, 2023-September 30, 2025, multivariate logistic regression analysis of Truveta real-time deidentified electronic health record data was performed. The percentage of COVID-19 outpatients aged ≥65 years who received an antiviral prescription was lower in spring 2024 (21%), fall-winter 2024-25 (23%), spring 2025 (16%), and summer 2025 (19%) than during other seasons (range = 37%-38%). Among those persons who received a prescription, 99% received it within 7 days of a positive SARS-CoV-2 test result or COVID-19 diagnosis, and 80% were prescribed nirmatrelvir/ritonavir. Among adults aged ≥65 years, the odds of receiving an antiviral prescription were higher among those aged 75-84 and ≥85 years (adjusted odds ratio [aOR] = 1.09 and 1.11, respectively), Asian (aOR = 1.42) or Hispanic or Latino persons (aOR = 1.24), and those who had received ≥1 COVID-19 vaccine dose (aOR = 1.73) than among adults in other age, racial, ethnic, and vaccination status groups. Persons with at least one comorbidity and rural residents had lower odds of receiving an antiviral prescription. Persons with COVID-19 had higher odds of receiving a COVID-19 antiviral prescription in summer 2024 (aOR = 1.05) compared with other analytic periods. Odds of prescribing were lower during periods of lower COVID-19 incidence. Antivirals might be underprescribed among adults aged ≥65 years, and prescribing rates vary temporally. Encouraging annual COVID-19 vaccination and increased prescribing of antivirals among adults aged ≥65 years with COVID-19 could reduce the risk for severe illness and hospitalization in this population.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 6","pages":"69-76"},"PeriodicalIF":16.2,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional Increases in Incidence of Coccidioidomycosis (Valley Fever) - Arizona, 2005-2022.","authors":"Sophia E Kruger, Irene Ruberto, Thomas Williamson, Justin V Remais, Alexandra K Heaney, Jennifer R Head","doi":"10.15585/mmwr.mm7506a3","DOIUrl":"10.15585/mmwr.mm7506a3","url":null,"abstract":"<p><p>Incidence of coccidioidomycosis (Valley fever), a fungal infection caused by inhalation of Coccidioides species spores, has increased substantially across the southwestern United States in association with increasing aridity, warming temperatures, and precipitation volatility. Arizona and California report >95% of U.S. coccidioidomycosis cases, and incidence in Arizona has increased statewide. Patterns within Arizona's distinct climatological regions have not been characterized, especially in regions outside the known zone of persistently high levels of disease occurrence (hyperendemicity) in the southwest Sonoran Desert region. In this study, surveillance data reported to the Arizona Department of Health Services since 2005 were used to calculate coccidioidomycosis incidence within six ecological regions. During 2005-2022, annual incidence approximately doubled in Arizona, with >95% of cases reported from the Sonoran Desert region. Although the Plateaus and Mojave Desert regions (in the northern parts of the state) reported <1.5% of Arizona cases during this period, these regions experienced the highest relative increases in incidence from the 2005-2007 period to the 2020-2022 period. During 2020-2022, coccidioidomycosis incidence in the Plateaus region was 6.61 times the incidence during 2005-2007 (95% CI = 4.22-10.30), and in the Mojave Desert region, incidence was 4.50 times that during 2005-2007 (95% CI = 3.45-5.89). The Plateau and Mojave regions also reported the highest relative increases in incidence from the 2014-2016 period to the 2020-2022 period. Large relative incidence increases in northern regions, including cooler and wetter regions generally considered less suitable for Coccidioides species establishment and transmission, necessitate targeted public health messaging in these areas and support ongoing investigation into the causes of these increases.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 6","pages":"85-91"},"PeriodicalIF":16.2,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12919847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudo-Outbreak of Purpureocillium lilacinum Skin Infections at a Dermatology Clinic - Washington, 2024.","authors":"Kyle S Yomogida, Emily Laskowski, Lisa Hannah, Elizabeth Sajewski, Paige Gable, Heather Moulton-Meissner, Kristen Clancy, Marissa Howard, Mitsuru Toda, Anastasia P Litvintseva, Lindsay A Parnell, Brian Schwem, Kimberly L McKinney, Amy L Valderrama, Kiran M Perkins, Samia N Naccache, Dallas J Smith","doi":"10.15585/mmwr.mm7505a2","DOIUrl":"10.15585/mmwr.mm7505a2","url":null,"abstract":"<p><p>In April 2024, a Washington dermatology clinic reported multiple cases of atypical fungal skin infections caused by the environmental mold Purpureocillium lilacinum to Clallam County Public Health. P. lilacinum most frequently causes skin infections among immunocompromised persons but can occasionally infect immunocompetent persons. The diagnoses were made on the basis of swab specimens collected from patients' skin to diagnose a fungal skin infection, rather than from a biopsy or skin scraping, as is recommended. An investigation by the Washington State Department of Health and CDC revealed this to be a pseudo-outbreak caused by contaminated saline, ultimately affecting 22 patients during January-October 2024. The investigation found that the clinic had refilled and reused saline squeeze bottles during skin swab collection. This resulted in contamination of the saline with P. lilacinum, which was transferred to the skin when swab specimens were obtained. Whole genome sequencing confirmed that P. lilacinum isolates from patient swab specimens were closely related to environmental isolates from the contaminated bottles. The clinic discontinued use of refillable squeeze bottles in January 2025 and transitioned to single-use saline packets, after which no further cases were reported. This investigation underscores the importance of proper diagnostic specimen collection procedures and infection prevention and control practices in clinical settings.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 5","pages":"64-67"},"PeriodicalIF":16.2,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12900387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146181025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Purpureocillium lilacinum Keratitis Outbreak Associated with an Ophthalmology Clinic - New York City, 2024.","authors":"Michelle E Chang, Elise Mantell, William G Greendyke, Brian Schwem, Zachary Mudge, Luisa F López, Dallas J Smith, Anastasia P Litvintseva, Adam Rowh, Heather Moulton-Meissner, Paige Gable, Tristan D McPherson","doi":"10.15585/mmwr.mm7505a1","DOIUrl":"10.15585/mmwr.mm7505a1","url":null,"abstract":"<p><p>In December 2024, a clinical laboratory notified the New York City Health Department of three patients with fungal keratitis caused by an unidentified mold following laser eye surgery at an ophthalmology clinic. All three patients experienced vision loss, and one patient required corneal transplantation. Corneal cultures from two of the patients grew Purpureocillium lilacinum, an environmental mold that can cause a range of infections in humans; eye infections have been reported. The clinic paused surgeries. The health department assessed the clinic's infection prevention and control (IPC) practices and identified multiple deficiencies, including incomplete instrument sterilization logs, absence of disinfectants approved for use on work surfaces, use of expired topical ocular medications, and opportunities for exposure to nonsterile water from cool-mist humidifiers in the procedure room. CDC environmental infection control guidelines recommend avoidance of cool-mist humidifiers in health care facilities. All environmental cultures were negative for P. lilacinum, but fungal amplicon sequencing detected P. lilacinum DNA in the tubing of a surgical device. No further cases were identified after implementation of recommended IPC measures and resumption of surgeries during January 2025. Adherence to published IPC guidance during all procedures in ambulatory settings can reduce the risk for health care-associated infections.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 5","pages":"59-63"},"PeriodicalIF":16.2,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12900386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146181062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Vol. 74, No. 41.","authors":"","doi":"10.15585/mmwr.mm7502a5","DOIUrl":"10.15585/mmwr.mm7502a5","url":null,"abstract":"","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 2","pages":"32"},"PeriodicalIF":17.3,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12806946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.","authors":"Avnika B Amin, Jennifer P Collins, Xiaoyu Dong, Andrew J Leidner, Jamie Loehr, Charlotte A Moser, Lucy A McNamara","doi":"10.15585/mmwr.mm7501a2","DOIUrl":"10.15585/mmwr.mm7501a2","url":null,"abstract":"<p><p>Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis. Serogroups B, C, W, and Y cause the majority of cases of this disease in the United States. These serogroups are targeted by different meningococcal vaccines available in the United States. Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY) (MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) and two serogroup B meningococcal vaccines (MenB) (MenB-4C [Bexsero, GSK] and MenB-FHbp [Trumenba, Pfizer]) are licensed for use in the United States and recommended by CDC's Advisory Committee on Immunization Practices (ACIP). Indications for MenACWY and MenB vaccination have not changed since indications for their use were published in 2020. A pentavalent (serogroups A, B, C, W, and Y) meningococcal vaccine (MenABCWY) (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer]) has been licensed and recommended for use since October 2023. On February 14, 2025, the Food and Drug Administration licensed a second pentavalent MenABCWY vaccine (MenACWY-CRM/MenB-4C [Penmenvy, GSK]) for prevention of invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y in persons aged 10-25 years, the same indication for which MenACWY-TT/MenB-FHbp is licensed. On April 16, 2025, ACIP recommended that MenACWY-CRM/MenB-4C may be used when both MenACWY and MenB are indicated at the same visit for 1) healthy persons aged 16-23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia). Different manufacturers' serogroup B-targeting vaccines are not interchangeable; therefore, when MenACWY-CRM/MenB-4C is used, MenB-4C should be used for the other MenB doses. This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-CRM/MenB-4C.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 1","pages":"7-14"},"PeriodicalIF":17.3,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zika Virus Outbreak - Bangladesh, September-December 2024.","authors":"Jannatul Ferdous, Md Abdullah Omar Nasif, Gretchen Cowman, Immamul Muntasir, Mohammad Rashedul Hassan, Md Omar Qayum, Kyaw Thowai Prue Prince, Ahmed Nawsher Alam, Manjur Hossain Khan Jony, Fariha Masfiqua Malek, Rozina Afroz, Mahbubur Rahman, Tahmina Shirin","doi":"10.15585/mmwr.mm7501a1","DOIUrl":"10.15585/mmwr.mm7501a1","url":null,"abstract":"<p><p>Zika virus infection is transmitted to humans primarily through the bite of infected Aedes species mosquitoes. Although most Zika virus disease cases are mild or asymptomatic, severe neurologic complications can occur. Infection during pregnancy can result in severe congenital anomalies. In Bangladesh, Zika virus was first detected in an archived specimen from 2014; subsequently, five cases of Zika virus disease were identified in 2023. In September 2024, in response to identification of a confirmed Zika virus disease case in Bangladesh's capital, Dhaka, in a woman aged 29 years who was initially thought to have dengue, the Institute of Epidemiology, Disease Control and Research (IEDCR) launched an outbreak investigation. After IEDCR notification to hospitals, five additional Zika virus disease cases were identified in four patients evaluated at three Dhaka hospitals and in a household contact of one of these patients. Another four Zika virus disease cases were identified through Zika virus testing of patients referred to IEDCR during a concurrent chikungunya outbreak. In total, 10 confirmed cases of Zika virus disease were detected in and around Dhaka during September-December 2024 in patients with no history of international travel. None of the patients was pregnant, and all recovered without hospitalization or complications. An entomological investigation detected Zika virus RNA in Aedes species mosquitoes in Dhaka. This investigation suggests sporadic Zika virus transmission occurs in Dhaka. Integrated testing and surveillance for arboviral diseases might improve detection of Zika virus disease and support clinical management in areas where transmission of multiple arboviral diseases occurs. Prevention of these infections through vector control and use of personal protective measures should also be emphasized.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"75 1","pages":"1-6"},"PeriodicalIF":16.2,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}